Advertisement

Pulmonary hypertension due to high cardiac output

Published:October 31, 2022DOI:https://doi.org/10.1016/j.rmed.2022.107034

      Highlights

      • High cardiac output is an uncommon but important cause of PH.
      • Increased flow through pulmonary circuit increases sheer stress and increases mPAP.
      • Important causes: high-output heart failure, cirrhosis, fistulas, obesity, anemia.
      • Treatment of underlying condition may lead to resolution of PH.

      Abstract

      Pulmonary hypertension (PH) is usually associated with a normal or decreased cardiac output (CO). Less commonly, PH can occur in the context of a hyperdynamic circulation, characterized by high CO (>8 L/min) and/or cardiac index ≥4 L/min/m2 in the setting of a decreased systemic vascular resistance. PH due to high CO can occur due to multiple conditions and in general remains understudied. In this review article we describe the pathophysiology, etiology, diagnosis, hemodynamic characteristics, and management of PH in the setting of high CO. It is important to recognize this distinct entity as PH tends to improve with treatment of the underlying etiology and PH specific therapies may worsen the hemodynamic state.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Respiratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Simonneau G.
        • et al.
        Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
        Eur. Respir. J. 2019; 53
        • Rich J.D.
        • Archer S.L.
        • Rich S.
        Noninvasive cardiac output measurements in patients with pulmonary hypertension.
        Eur. Respir. J. 2013; 42: 125-133
        • Reddy Y.N.V.
        • et al.
        High-output heart failure: a 15-year experience.
        J. Am. Coll. Cardiol. 2016; 68: 473-482
        • Alvarado E.
        • et al.
        The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis.
        J. Hepatol. 2018; 69: 746-747
        • Iwakiri Y.
        • Groszmann R.J.
        The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.
        Hepatology. 2006; 43: S121-S131
        • Licata A.
        • et al.
        Clinical implications of the hyperdynamic syndrome in cirrhosis.
        Eur. J. Intern. Med. 2014; 25: 795-802
        • Wasse H.
        • Singapuri M.S.
        High-output heart failure: how to define it, when to treat it, and how to treat it.
        Semin. Nephrol. 2012; 32: 551-557
        • Jiang X.
        • et al.
        Hyperdynamic circulation and cardiovascular risk in children and adolescents. The Bogalusa Heart Study.
        Circulation. 1995; 91: 1101-1106
        • Okura H.
        • Takatsu Y.
        High-output heart failure as a cause of pulmonary hypertension.
        Intern. Med. 1994; 33: 363-365
        • Spruijt O.A.
        • Bogaard H.J.
        • Vonk-Noordegraaf A.
        Pulmonary arterial hypertension combined with a high cardiac output state: three remarkable cases.
        Pulm. Circ. 2013; 3: 440-443
        • Bossone E.
        • Naeije R.
        Exercise-induced pulmonary hypertension.
        Heart Fail. Clin. 2012; 8: 485-495
        • Kovacs G.
        • et al.
        Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review.
        Eur. Respir. J. 2009; 34: 888-894
        • Reeves J.T.
        • Linehan J.H.
        • Stenmark K.R.
        Distensibility of the normal human lung circulation during exercise.
        Am. J. Physiol. Lung Cell Mol. Physiol. 2005; 288: L419-L425
        • Lewis G.D.
        • et al.
        Pulmonary vascular hemodynamic response to exercise in cardiopulmonary diseases.
        Circulation. 2013; 128: 1470-1479
        • Cartin-Ceba R.
        • Krowka M.J.
        Portopulmonary hypertension.
        Clin. Liver Dis. 2014; 18: 421-438
        • Cumbo-Nacheli G.
        • Tonelli A.
        Effect of pneumonectomy on pulmonary artery pressure and right ventricular function.
        Chirurgia (Bucur). 2013; 26: 73-78
        • Foroulis C.N.
        • et al.
        Study on the late effect of pneumonectomy on right heart pressures using Doppler echocardiography.
        Eur. J. Cardio. Thorac. Surg. 2004; 26: 508-514
        • D'Alto M.
        • Mahadevan V.S.
        Pulmonary arterial hypertension associated with congenital heart disease.
        Eur. Respir. Rev. 2012; 21: 328-337
        • Diller G.P.
        • et al.
        Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.
        Circulation. 2008; 117: 3020-3030
        • Khirfan G.
        • et al.
        Comparison of different methods to estimate cardiac index in pulmonary arterial hypertension.
        Circulation. 2019; 140: 705-707
        • McKie P.M.
        • et al.
        Amelioration of high cardiac output and pulmonary hypertension by occlusion of congenital porto-systemic shunt.
        Circulation. 2012; 126: 2533-2534
        • Mehta P.A.
        • Dubrey S.W.
        High output heart failure.
        QJM. 2009; 102: 235-241
        • Singh S.
        • Sharma S.
        High-output cardiac failure.
        in: StatPearls. 2022 (Treasure Island (FL)
        • Anand I.S.
        • Florea V.G.
        High output cardiac failure.
        Curr. Treat. Options Cardiovasc. Med. 2001; 3: 151-159
        • Gupta V.
        • Tonelli A.R.
        • Krasuski R.A.
        Congenital heart disease and pulmonary hypertension.
        Heart Fail. Clin. 2012; 8: 427-445
        • Sahay S.
        • Krasuski R.A.
        • Tonelli A.R.
        Partial anomalous pulmonary venous connection and pulmonary arterial hypertension.
        Respirology. 2012; 17: 957-963
        • Baumgartner H.
        • et al.
        ESC Guidelines for the management of adult congenital heart disease.
        Eur. Heart J. 2020; 42 (2021): 563-645
        • Iwakiri Y.
        Pathophysiology of portal hypertension.
        Clin. Liver Dis. 2014; 18: 281-291
        • AbuHalimeh B.
        • Krowka M.J.
        • Tonelli A.R.
        Treatment barriers in portopulmonary hypertension.
        Hepatology. 2019; 69: 431-443
        • Savale L.
        • et al.
        Portopulmonary hypertension in the current era of pulmonary hypertension management.
        J. Hepatol. 2020; 73: 130-139
        • Thomas C.
        • et al.
        Portopulmonary hypertension: from bench to bedside.
        Front. Med. 2020; 7569413
        • Krowka M.J.
        Portopulmonary hypertension.
        Semin. Respir. Crit. Care Med. 2012; 33: 17-25
        • DuBrock H.M.
        • et al.
        Outcomes of liver transplantation in treated portopulmonary hypertension patients with a mean pulmonary arterial pressure >/=35 mm Hg.
        Transplant Direct. 2020; 6: e630
        • DuBrock H.M.
        • Del Valle K.T.
        • Krowka M.J.
        Mending the Model for end-stage liver disease: an in-depth review of the past, present, and future portopulmonary hypertension Model for end-stage liver disease exception.
        Liver Transplant. 2022; 28: 1224-1230
        • Tsao C.W.
        • et al.
        Heart disease and stroke statistics-2022 update: a report from the American heart association.
        Circulation. 2022; 145: e153-e639
        • de Divitiis O.
        • et al.
        Obesity and cardiac function.
        Circulation. 1981; 64: 477-482
        • Stelfox H.T.
        • et al.
        Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume.
        Crit. Care Med. 2006; 34: 1243-1246
        • McQuillan B.M.
        • et al.
        Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects.
        Circulation. 2001; 104: 2797-2802
        • Ayinapudi K.
        • et al.
        Obesity and pulmonary hypertension.
        Curr. Hypertens. Rep. 2018; 20: 99
        • Wahab A.
        • et al.
        Obesity, systemic hypertension, and pulmonary hypertension: a tale of three diseases.
        Curr. Probl. Cardiol. 2021; 46100599
        • Khirfan G.
        • et al.
        Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Obese Patients.
        Chest, 2022
        • Adler A.C.
        • et al.
        Effects of body surface area-indexed calculations in the morbidly obese: a mathematical analysis.
        J. Cardiothorac. Vasc. Anesth. 2013; 27: 1140-1144
        • Khirfan G.
        • et al.
        Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?.
        J. Heart Lung Transplant. 2021; 40: 614-622
        • Siu C.W.
        • et al.
        Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study.
        J. Clin. Endocrinol. Metab. 2007; 92: 1736-1742
        • Teasdale S.L.
        • et al.
        Hyperdynamic right heart function in graves' hyperthyroidism measured by echocardiography normalises on restoration of euthyroidism.
        Heart Lung Circ. 2017; 26: 580-585
        • Sugiura T.
        • et al.
        Autoimmunity and pulmonary hypertension in patients with Graves' disease.
        Heart Ves. 2015; 30: 642-646
        • Durstenfeld M.S.
        • Hsue P.Y.
        An unusual, reversible cause of acute high-output heart failure complicated by refractory shock.
        Circulation. 2020; 142: 901-905
        • Yamasaki H.
        • et al.
        Reversible pulmonary hypertension, lactic acidosis, and rapidly evolving multiple organ failure as manifestations of shoshin beriberi.
        Circ. J. 2010; 74: 1983-1985
        • Gordeuk V.R.
        • Castro O.L.
        • Machado R.F.
        Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.
        Blood. 2016; 127: 820-828
        • Machado R.F.
        • Farber H.W.
        Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.
        Clin. Chest Med. 2013; 34: 739-752
        • Klings E.S.
        • et al.
        An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.
        Am. J. Respir. Crit. Care Med. 2014; 189: 727-740
        • Poludasu S.
        • et al.
        Left ventricular systolic function in sickle cell anemia: a meta-analysis.
        J. Card. Fail. 2013; 19: 333-341
        • Adir Y.
        • Elia D.
        • Harari S.
        Pulmonary hypertension in patients with chronic myeloproliferative disorders.
        Eur. Respir. Rev. 2015; 24: 400-410
        • Krishnan U.
        • et al.
        Pulmonary hypertension complicating multiple myeloma.
        Pulm. Circ. 2015; 5: 590-597
        • Albakri A.
        High output heart failure: a review of clinical status-epidemiology, pathophysiology, diagnosis, prognosis and clinical management.
        Med. Clin. 2019; 3: 1-10
        • Brohee D.
        • et al.
        High-output right ventricular failure secondary to hepatic arteriovenous microfistulae. Selective arterial embolization treatment.
        Arch. Intern. Med. 1984; 144: 1282-1284
        • Agarwal A.K.
        Systemic effects of hemodialysis access.
        Adv. Chron. Kidney Dis. 2015; 22: 459-465
        • Arunachalam A.
        • Chaisson N.F.
        • Tonelli A.R.
        Methods to improve the yield of right heart catheterization in pulmonary hypertension.
        Respir. Med. X. 2020; 2100015
        • Arevalo C.
        • et al.
        Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: a single center experience.
        Respir. Med. 2021; 188106596
        • Narechania S.
        • Tonelli A.R.
        Hemodynamic consequences of a surgical arteriovenous fistula.
        Ann Am Thorac Soc. 2016; 13: 288-291
        • Kawar B.
        • et al.
        Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications.
        Am. J. Nephrol. 2013; 37: 281-290
        • Devasahayam J.
        • et al.
        Pulmonary hypertension in end-stage renal disease.
        Respir. Med. 2020; 164105905
        • Anjum H.
        • Surani S.
        Pulmonary hypertension in pregnancy: a review.
        Medicina (Kaunas). 2021; 57
        • Krishnan S.
        • et al.
        Pulmonary hypertension complicating pregnancy.
        Current Pulmonology Reports. 2021; 10: 71-83
        • Held M.
        • et al.
        Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation.
        Eur. Respir. J. 2014; 43: 156-165
        • Condon D.F.
        • et al.
        The 6th World Symposium on Pulmonary Hypertension: What's Old Is New. F1000Res. 2019: 8
        • Boucly A.
        • et al.
        Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension.
        Am. J. Respir. Crit. Care Med. 2021; 204: 842-854
        • Bonderman D.
        • et al.
        Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
        Circulation. 2013; 128: 502-511
        • Rich S.
        • McLaughlin V.V.
        The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.
        J. Am. Coll. Cardiol. 1999; 34: 1184-1187
        • Carroll D.L.
        • Malecki-Ketchell A.
        • Astin F.
        Non-pharmacological interventions to reduce psychological distress in patients undergoing diagnostic cardiac catheterization: a rapid review.
        Eur. J. Cardiovasc. Nurs. 2016; 16: 92-103
        • Shah S.
        • et al.
        Effects of psychological stress on vascular physiology: beyond the current imaging signal.
        Curr. Cardiol. Rep. 2020; 22: 156
        • Melillo C.A.
        • et al.
        Repeatability of pulmonary pressure measurements in patients with pulmonary hypertension.
        Ann Am Thorac Soc. 2020; 17: 1028-1030
        • Schachinger H.
        • et al.
        Mental stress increases right heart afterload in severe pulmonary hypertension.
        Clin. Physiol. 2000; 20: 483-487
        • Mazzuero G.
        • Temporelli P.L.
        • Tavazzi L.
        Influence of mental stress on ventricular pump function in postinfarction patients. An invasive hemodynamic investigation.
        Circulation. 1991; 83: II145-I154
        • Galie N.
        • et al.
        ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT).
        Eur. Heart J. 2015; 37 (2016): 67-119
        • Ahmed M.
        • Dweik R.A.
        • Tonelli A.R.
        What is the best approach to a high systolic pulmonary artery pressure on echocardiography?.
        Cleve. Clin. J. Med. 2016; 83: 256-260
        • Frost A.
        • et al.
        Diagnosis of pulmonary hypertension.
        Eur. Respir. J. 2019; 53
        • Fares W.H.
        • et al.
        Thermodilution and Fick cardiac outputs differ: impact on pulmonary hypertension evaluation.
        Cancer Res. J. 2012; 19: 261-266
        • Opotowsky A.R.
        • et al.
        Thermodilution vs estimated Fick cardiac output measurement in clinical practice: an analysis of mortality from the veterans affairs clinical assessment, reporting, and tracking (VA CART) program and vanderbilt university.
        JAMA Cardiol. 2017; 2: 1090-1099
        • Ascha M.
        • et al.
        Pulse oximetry and arterial oxygen saturation during cardiopulmonary exercise testing.
        Med. Sci. Sports Exerc. 2018; 50: 1992-1997
        • Mandras S.A.
        • Mehta H.S.
        • Vaidya A.
        Pulmonary hypertension: a brief guide for clinicians.
        Mayo Clin. Proc. 2020; 95: 1978-1988
        • Aller R.
        • et al.
        The effect of liver transplantation on circulating levels of estradiol and progesterone in male patients: parallelism with hepatopulmonary syndrome and systemic hyperdynamic circulation improvement.
        J. Endocrinol. Invest. 2001; 24: 503-509
        • Houlihan D.D.
        • et al.
        Review article: liver transplantation for the pulmonary disorders of portal hypertension.
        Aliment. Pharmacol. Ther. 2013; 37: 183-194
        • Raevens S.
        • et al.
        Pulmonary abnormalities in liver disease: relevance to transplantation and outcome.
        Hepatology. 2021; 74: 1674-1686
        • Qaiser K.N.
        • Tonelli A.R.
        Novel treatment pathways in pulmonary arterial hypertension.
        Methodist Debakey Cardiovasc J. 2021; 17: 106-114
        • Faisal M.
        • et al.
        Effect of PAH specific therapy on pulmonary hemodynamics and six-minute walk distance in portopulmonary hypertension: a systematic review and meta-analysis.
        Pulm Med. 2014; (2014)528783